Related Experiment Video
Updated: May 23, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: mechanistic networks and
Xuejia Wang1, Guangzhen Lu2, Yingxue Zhou1
1Shandong First Medical University, Jinan, China.
Aims:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent worldwide and may progress to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma, yet effective pharmacological therapies remain limited. This review summarizes current evidence on the therapeutic potential and mechanistic basis of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in MASLD.
Methods:
We synthesize findings from preclinical models and clinical studies evaluating GLP-1RAs in MASLD/MASH, with emphasis on hepatic metabolic pathways, inflammatory and fibrogenic signaling, and gut-liver axis mechanisms, as well as outcomes from clinical trials and emerging multi-agonist strategies.
Results:
Clinical studies support the therapeutic relevance of GLP-1RAs in MASLD/MASH by demonstrating reductions in liver fat content, improvements in liver enzyme profiles, and favorable histologic changes, particularly with semaglutide and emerging multi-agonist therapies in selected populations. Preclinical and translational studies further suggest that these benefits may be mediated through integrated effects on hepatic lipid handling, oxidative and inflammatory stress, fibrogenic signaling, and the gut-liver axis, although the relative contribution of direct hepatic versus indirect systemic mechanisms remains incompletely resolved.
Conclusions:
Current evidence supports an expanding role for GLP-1-based therapies in metabolic liver disease and provides a mechanistic framework for their continued development and clinical evaluation in MASLD.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

